Matches in DBpedia 2014 for { ?s ?p Ledipasvir (formerly GS-5885) is an experimental drug for the treatment of hepatitis C being developed by Gilead Sciences. After completing Phase III clinical trials, on Feb 10, 2014 Gilead filed for U.S. Approval of a Ledipasvir/Sofosbuvir Fixed-Dose combination tablet for Genotype 1 Hepatitis C. The Solvadi (sufosbuvir) /Ledipasvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without peg-interferon.Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein.Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the nucleotide analogue inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1. Gilead is developing a sofosbuvir + ledipasvir coformulation that is being tested with and without ribavirin. In February 2014 Gilead has filed for FDA approval of ledipasvir + sofosbuvir oral treatment, without interferon and ribavirin.. }
Showing items 1 to 1 of
1
with 100 items per page.
- Ledipasvir abstract "Ledipasvir (formerly GS-5885) is an experimental drug for the treatment of hepatitis C being developed by Gilead Sciences. After completing Phase III clinical trials, on Feb 10, 2014 Gilead filed for U.S. Approval of a Ledipasvir/Sofosbuvir Fixed-Dose combination tablet for Genotype 1 Hepatitis C. The Solvadi (sufosbuvir) /Ledipasvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without peg-interferon.Ledipasvir is an inhibitor of the hepatitis C virus HCV NS5A protein.Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the nucleotide analogue inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1. Gilead is developing a sofosbuvir + ledipasvir coformulation that is being tested with and without ribavirin. In February 2014 Gilead has filed for FDA approval of ledipasvir + sofosbuvir oral treatment, without interferon and ribavirin.".